Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Exogenous glucagon-like peptide-1 for hyperglycemia in critically ill patients.

Pinelli NR, Jones MC, Monday LM, Smith Z, Rhoney DH.

Ann Pharmacother. 2012 Jan;46(1):124-9. doi: 10.1345/aph.1Q417. Epub 2011 Dec 27. Review.

PMID:
22202493
2.

The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study.

Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M.

Crit Care. 2009;13(3):R67. doi: 10.1186/cc7874. Epub 2009 May 13.

3.

The glucoregulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study.

Galiatsatos P, Gibson BR, Rabiee A, Carlson O, Egan JM, Shannon RP, Andersen DK, Elahi D.

Crit Care Med. 2014 Mar;42(3):638-45. doi: 10.1097/CCM.0000000000000035.

PMID:
24247476
4.

Intensive insulin therapy for critically ill patients.

Lewis KS, Kane-Gill SL, Bobek MB, Dasta JF.

Ann Pharmacother. 2004 Jul-Aug;38(7-8):1243-51. Epub 2004 Jun 8.

PMID:
15187219
5.

Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes.

Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck MA, Holst JJ, Schmidt WE, Gallwitz B.

Crit Care Med. 2004 Mar;32(3):848-51.

PMID:
15090972
6.

Glucose control in the intensive care unit.

Fahy BG, Sheehy AM, Coursin DB.

Crit Care Med. 2009 May;37(5):1769-76. doi: 10.1097/CCM.0b013e3181a19ceb. Review.

PMID:
19325461
7.

Hyperglycemia management using insulin in the acute care setting: therapies and strategies for care in the non-critically ill patient.

Kirk JK, Oldham EC.

Ann Pharmacother. 2010 Jul-Aug;44(7-8):1222-30. doi: 10.1345/aph.1M695. Epub 2010 Jun 22. Review.

PMID:
20571106
8.

Addressing hyperglycemia from hospital admission to discharge.

Moghissi ES.

Curr Med Res Opin. 2010 Mar;26(3):589-98. doi: 10.1185/03007990903566822. Review.

PMID:
20078323
9.

Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting.

Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ Jr, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP.

Am J Cardiol. 2007 Sep 1;100(5):824-9. Epub 2007 Jun 14.

PMID:
17719327
10.

Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes.

Deane AM, Summers MJ, Zaknic AV, Chapman MJ, Fraser RJ, Di Bartolomeo AE, Wishart JM, Horowitz M.

Crit Care. 2011;15(1):R35. doi: 10.1186/cc9983. Epub 2011 Jan 21.

11.

Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.

Iltz JL, Baker DE, Setter SM, Keith Campbell R.

Clin Ther. 2006 May;28(5):652-65. Review.

PMID:
16861088
12.

Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.

Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W.

Regul Pept. 2004 Apr 15;118(1-2):89-97. Erratum in: Regul Pept. 2005 Nov 15;131(1-3):111. Gallwitz, J Baptist [corrected to Gallwitz, Baptist].

PMID:
14759561
13.

Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials.

Pittas AG, Siegel RD, Lau J.

Arch Intern Med. 2004 Oct 11;164(18):2005-11.

PMID:
15477435
14.

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure.

Halbirk M, Nørrelund H, Møller N, Holst JJ, Schmitz O, Nielsen R, Nielsen-Kudsk JE, Nielsen SS, Nielsen TT, Eiskjaer H, Bøtker HE, Wiggers H.

Am J Physiol Heart Circ Physiol. 2010 Mar;298(3):H1096-102. doi: 10.1152/ajpheart.00930.2009. Epub 2010 Jan 15.

15.

[Glycaemia control in critically ill patients is justified and effective].

Rybka J.

Vnitr Lek. 2010 Sep;56(9 Suppl):977-87. Review. Czech.

PMID:
21137171
16.

Intravenous GLP-1 (7-36) amide for prevention of hyperglycemia during cardiac surgery: a randomized, double-blind, placebo-controlled study.

Kohl BA, Hammond MS, Cucchiara AJ, Ochroch EA.

J Cardiothorac Vasc Anesth. 2014 Jun;28(3):618-25. doi: 10.1053/j.jvca.2013.06.021. Epub 2013 Oct 19.

PMID:
24144627
17.

Clinical potential of insulin therapy in critically ill patients.

Mesotten D, Van den Berghe G.

Drugs. 2003;63(7):625-36. Review.

PMID:
12656643
18.

Dysglycaemia in the critically ill - significance and management.

Deane AM, Horowitz M.

Diabetes Obes Metab. 2013 Sep;15(9):792-801. doi: 10.1111/dom.12078. Epub 2013 Feb 25. Review.

PMID:
23368662
19.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
20.

Hyperglycemia in the hospital setting: the case for improved control among non-diabetics.

Conner TM, Flesner-Gurley KR, Barner JC.

Ann Pharmacother. 2005 Mar;39(3):492-501. Epub 2005 Feb 8. Review.

PMID:
15701779

Supplemental Content

Support Center